Study: Pharma Companies at Lower Than Expected Risk from Social Media Usage
A study by Visible Technologies finds that only a tiny percentage of all posts across social media sites rise to the level of the Adverse Event Reporting (AER) government mandate. The AER requires that companies explain negative side effects from the use of a drug in a clinical trial. Only .3 percent of posts had an AER and some of those didn’t actually rise to the government threshold to mandate one.
Greg Singh, regional director of Visible says the results show that while pharma companies “are intimidated by the FDA’s Adverse Events Reporting requirements,” they shouldn’t be quite as hesitant on social media as they have been.
“These findings prove that AER reporting is far less common than people think, creating a safer harbor for pharmaceutical marketers who want to embrace the many opportunities that social media offers to engage with consumers and build brand loyalty.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in